Frontline treatment of a genetically heterogeneous group of patients newly diagnosed with AML who received either intensive combination chemotherapy or venetoclax-based lower-intensity therapy. Treatment- and patient-specific factors will determine the prognostic biomarkers that may differ between treatment groups (middle panel), which produce survival curves relevant to each treatment group.